Montz Harcus Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$739K Sell
2,937
-77
-3% -$16.6K 0.26% 38
2026
Q1
$655K Buy
3,014
+158
+6% +$35K 0.26% 42
2025
Q4
$653K Buy
2,856
+563
+25% +$128K 0.26% 39
2025
Q3
$531K Buy
2,293
+61
+3% +$12.4K 0.23% 45
2025
Q2
$414K Buy
2,232
+14
+0.6% +$2.6K 0.2% 45
2025
Q1
$465K Buy
2,218
+14
+0.6% +$2.72K 0.25% 43
2024
Q4
$392K Buy
2,204
+245
+13% +$45K 0.22% 45
2024
Q3
$387K Buy
1,959
+17
+0.9% +$3.17K 0.23% 44
2024
Q2
$333K Sell
1,942
-437
-18% -$72.4K 0.22% 43
2024
Q1
$433K Buy
2,379
+424
+22% +$73.1K 0.29% 38
2023
Q4
$303K Buy
1,955
+27
+1% +$3.94K 0.23% 39
2023
Q3
$287K Buy
1,928
+37
+2% +$5.43K 0.25% 38
2023
Q2
$255K Buy
1,891
+3
+0.2% +$440 0.21% 44
2023
Q1
$301K Buy
1,888
+55
+3% +$8.41K 0.28% 39
2022
Q4
$296K Buy
1,833
+3
+0.2% +$460 0.29% 40
2022
Q3
$246K Buy
1,830
+2
+0.1% +$287 0.27% 39
2022
Q2
$280K Buy
1,828
+132
+8% +$20.2K 0.3% 39
2022
Q1
$275K Buy
1,696
+3
+0.2% +$436 0.25% 42
2021
Q4
$229K Buy
+1,693
New +$200K 0.2% 48

Other funds holding ABBV

Montz Harcus Wealth Management's ABBV Position: Q2 2026 in Review

Montz Harcus Wealth Management reduced its AbbVie (ABBV) stake by 2.6% in Q2 2026, selling an estimated $16.6K and leaving 2,937 shares worth $739K. The position accounts for 0.26% of the portfolio, ranked #38.

Montz Harcus Wealth Management first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Montz Harcus Wealth Management held 2,937 shares of AbbVie worth $739K as of Q2 2026.
  • Montz Harcus Wealth Management sold 77 AbbVie shares in Q2 2026, an estimated $16.6K.
  • AbbVie made up 0.26% of Montz Harcus Wealth Management's portfolio in Q2 2026, its #38 holding.
  • Montz Harcus Wealth Management first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Montz Harcus Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.